Stock Analysis of Aeglea Bio Therapeutics Inc (AGLE) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code AGLE
Close 12.01
Change 0.970 / 8.79 %
Volume 43238.00
Vol Change 37332.00 / 632.10 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Aeglea Bio Therapeutics Inc
PE (TTM)

-976.16

Very Poor
Price / Book

5076.18

Very Poor
Price / Sales

272754

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

48627.65 K

Enterprise Value

48627.65 K

ROA (TTM)

-221.11

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-27941.56

Very Poor
Revenue

54.74 %

1054.00 K
Net Profit

251.29 %

-294432.00 K
Debt to Equity

0

Excellent
Altman Z Score

Indecisive
Quick Ratio

0

Poor
Cash Ratio

0

Poor


Highs/Lows of Aeglea Bio Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week10.5 14.38 % 1.54 % 12.33998.7627-Nov-2321-Nov-23
Two Week10.18 17.98 % 3.42 % 12.33998.7627-Nov-2321-Nov-23
One Month10.66 12.66 % 5.60 % 12.53998.4330-Oct-2310-Nov-23
Three Month0.523 2196.37 % 5.95 % 16.2620.470108-Sep-2307-Sep-23
Six Months0.1352 8783.14 % 17.48 % 16.2620.106408-Sep-2321-Jun-23
One year1.24 868.55 % 27.52 % 16.2620.106408-Sep-2321-Jun-23
Two year6.45 86.20 % 29.70 % 16.2620.106408-Sep-2321-Jun-23
Five year8.08 48.64 % 85.46 % 16.2620.106408-Sep-2321-Jun-23


Technical View of Aeglea Bio Therapeutics Inc
RSI

59.23

Neutral
MACD

-0.0445

Strong Bullish
ADX

13.20

Bullish
Super Trend

12.24

Mild Bearish
Williams %R

-8.44

Mild Bullish
CCI

104.72

Mild Bullish


EMA 5

11.03

Strong Bullish
EMA 15

10.73

Bullish
EMA 50

10.07

Strong Bullish
EMA 100

7.85

Bullish
SMA 100

6.79

Bullish
SMA 200

3.53

Bullish
SMA 5 / 20

10.78 / 10.64

Mild Bullish
SMA 15 / 50

10.35 / 11.42

Mild Bearish
SMA 50 / 200

11.42 / 3.53

Strong Bullish




Charts of Aeglea Bio Therapeutics Inc


Returns of Aeglea Bio Therapeutics Inc with Peers
Period / StockAGLENTRBDAREABIO
1 Week14.38%33.04%56.30%-4.03%
1 Mth12.66%4.68%71.67%3.74%
3 Mth2196.37%80.97%34.32%99.40%
6mth8783.14%99.55%41.49%83.98%
1 Year868.55%37.54%-52.88%57.82%
2 Year86.20%30.05%-57.05%41.70%
5 Years48.64%-79.97%-45.53%-64.61%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aeglea Bio Therapeutics Inc with Peers
Ratio / StockAGLENTRBDAREABIO
PE-976.16-5.76-1.21-2195.73
P/B5076.185.51-10.82316.84
ROA-221.11-75.42-127.85-13.92
ROE0-95.650-14.43
Debt To Equity00.0375-0.0930.0021
Revenue1054.00 K
54.74 % 		2085.31 K
0.274 % 		1000000
99.99 % 		0
%
Net Income-294432.00 K
251.29 % 		-5485.31 K
22.35 % 		-41047.05 K
99.87 % 		-5424.00 K
45.36 %


Technicals of Aeglea Bio Therapeutics Inc with Peers
Technical / StockAGLENTRBDAREABIO-
ADX13.2029.6321.3046.38
CMF-0.0095-0.107-0.2820.153
MFI42.4986.4191.3143.70
RSI59.2360.8970.9051.42
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MATrueTrueTrueTrue-
Price Above 200 MATrueTrueTrueTrue-


About : Aeglea Bio Therapeutics Inc

Address : 805 Las Cimas Parkway, Austin, TX, United States, 78746
Tel : 512 942 2935
URL : https://www.aeglea.com
Code : AGLE, ISIN : US00773J1034, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Apr_2016
Employee Count : 69

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.


Note : All Data Generated at the End of Trading Hours (EOD Data)